Sylvester Comprehensive Cancer Center

  • PLX120-03 - De La Fuente, Macarena

  • Investigator:
    Macarena De La Fuente
    RCname Email

    		Coordinator:
    RCemailImg Yaima de la Fuente
    RCphone 305-243-2441

    IRB: 20150830

    		SDG: Neurological Cancer
    Disease Site(s):

    Bones and Joints
    Sponsor: Plexxikon

    Enrolling Sites:

    Sylvester
    Title:

    A Phase 1/2a Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patients with Advanced, Unresectable Solid Tumors
    Eligibility Criteria - NCT02428712 *This information has been extracted from " www.clinicaltrials.gov"

  • Alliance A071401 - De La Fuente, Macarena

  • Investigator:
    Macarena De La Fuente
    RCname Email

    		Coordinator:
    RCemailImg Nathalie Padron
    RCphone +1 (305) 2439610

    IRB: 20151026

    		SDG: Neurological Cancer
    Disease Site(s):

    Brain and Nervous System
    Sponsor: Alliance for Clinical Trials in Oncology

    Enrolling Sites:

    Deerfield
    Kendall
    Sylvester
    Title:

    A071401: Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
    Eligibility Criteria - NCT02523014 *This information has been extracted from " www.clinicaltrials.gov"

  • 20180606 - De La Fuente Macarena

  • Investigator:
    Macarena De La Fuente
    RCname Email

    		Coordinator:
    RCemailImg Nathalie Padron
    RCphone +1 (305) 2439610

    IRB: 20180606

    		SDG: Neurological Cancer
    Disease Site(s):

    Brain and Nervous System
    Sponsor: SCCC

    Enrolling Sites:

    Sylvester
    Title:

    Non-invasive glioma characterization through molecular imaging
    Eligibility Criteria - NCT03684109 *This information has been extracted from " www.clinicaltrials.gov"

  • GCAR-7213 - De La Fuente, Macarena

  • Investigator:
    Macarena De La Fuente
    RCname Email

    		Coordinator:
    RCemailImg Yaima de la Fuente
    RCphone 305-243-2441

    IRB: 20190401

    		SDG: Neurological Cancer
    Disease Site(s):

    Brain and Nervous System
    Sponsor: GCAR

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester
    UMH
    Title:

    GBM AGILE MASTER PROTOCOL:GBM AGILE Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent Glioblastoma (GBM)
    Eligibility Criteria - NCT03970447 *This information has been extracted from " www.clinicaltrials.gov"

  • 20201293 - De La Fuente Macarena

  • Investigator:
    Macarena De La Fuente
    RCname Email

    		Coordinator:
    RCemailImg Yaima de la Fuente
    RCphone 305-243-2441

    IRB: 20201293

    		SDG: Neurological Cancer
    Disease Site(s):

    Brain and Nervous System
    Sponsor: Denovo

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester
    Title:

    A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Enzastaurin Added to Temozolomide During and Following Radiation Therapy in Newly Diagnosed Glioblastoma Patients Who Possess the Novel Genomic Biomarker DGM1
    Eligibility Criteria - NCT03776071 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210578 - De La Fuente Macarena

  • Investigator:
    Macarena De La Fuente
    RCname Email

    		Coordinator:
    RCemailImg Brenda Obana

    IRB: 20210578

    		SDG: Neurological Cancer
    Disease Site(s):

    Brain and Nervous System
    Sponsor: Pyramid Biosciences

    Enrolling Sites:

    Sylvester
    Title:

    A Phase 1/2 Study of PBI-200 in Subjects With NTRK-Fusion-Positive Advanced or Metastatic Solid Tumors
    Eligibility Criteria - NCT04901806 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210682 - De La Fuente Macarena

  • Investigator:
    Macarena De La Fuente
    RCname Email

    		Coordinator:
    RCemailImg Yaima de la Fuente
    RCphone 305-243-2441

    IRB: 20210682

    		SDG: Neurological Cancer
    Disease Site(s):

    Brain and Nervous System
    Sponsor: ETCTN

    Enrolling Sites:

    Deerfield
    Gables
    Plantation
    Sylvester
    Title:

    A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors
    Eligibility Criteria - NCT03212274 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210950 - De La Fuente Macarena

  • Investigator:
    Macarena De La Fuente
    RCname Email

    		Coordinator:

    IRB: 20210950

    		SDG: Neurological Cancer
    Disease Site(s):
    Sponsor: SCCC

    Enrolling Sites:

    Sylvester
    Title:

    Olutasidenib (FT-2102) Treatment Plan for a Patient with an Advanced Solid Tumor or Glioma with an IDH1 Mutation

  • A071601 - Heros, Deborah

  • Investigator:
    Deborah Heros
    RCname Email

    		Coordinator:
    RCemailImg Alain Fernandez Marrero
    RCphone +1 (305) 2439553 x9553

    IRB: 20180772

    		SDG: Neurological Cancer
    Disease Site(s):

    Brain and Nervous System
    Sponsor: Alliance for Clinical Trials in Oncology

    Enrolling Sites:

    Sylvester
    Title:

    A071601: Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas
    Eligibility Criteria - NCT03224767 *This information has been extracted from " www.clinicaltrials.gov"

  • 20200502 - Heros Deborah

  • Investigator:
    Deborah Heros
    RCname Email

    		Coordinator:
    RCemailImg Nathalie Padron
    RCphone +1 (305) 2439610

    IRB: 20200502

    		SDG: Neurological Cancer
    Disease Site(s):

    Multiple
    Sponsor: Alliance for Clinical Trials in Oncology

    Enrolling Sites:

    Sylvester
    UMH
    Title:

    Genomically-Guided Treatment Trial in Brain Metastases
    Eligibility Criteria - NCT03994796 *This information has been extracted from " www.clinicaltrials.gov"

  • EAF151 - Heros, Deborah

  • Investigator:
    Deborah Heros
    RCname Email

    		Coordinator:
    RCemailImg Nathalie Padron
    RCphone +1 (305) 2439610

    IRB: 20200503

    		SDG: Neurological Cancer
    Disease Site(s):

    Brain and Nervous System
    Sponsor: ECOG

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester
    UMH
    Title:

    Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma
    Eligibility Criteria - NCT03115333 *This information has been extracted from " www.clinicaltrials.gov"

  • NRG-BN003 - Mellon, Eric

  • Investigator:
    Eric Mellon
    RCname Email

    		Coordinator:

    IRB: 20170631

    		SDG: Neurological Cancer
    Disease Site(s):

    Brain and Nervous System
    Sponsor: NRG

    Enrolling Sites:

    Deerfield
    Gables
    JMH
    Sylvester
    Title:

    NRG-BN003:Phase III Trial Of Observation Versus Irradiation For A Gross Totally Resected Grade II Meningioma
    Eligibility Criteria - NCT03180268 *This information has been extracted from " www.clinicaltrials.gov"

  • CCTG CE.7 - Mellon, Eric

  • Investigator:
    Eric Mellon
    RCname Email

    		Coordinator:
    RCemailImg Lilly Sanchez
    RCphone +1 (305) 2430974

    IRB: 20190176

    		SDG: Neurological Cancer
    Disease Site(s):

    Brain and Nervous System
    Sponsor: CCTG

    Enrolling Sites:

    Deerfield
    Gables
    Plantation
    Sylvester
    Title:

    CCTG CE.7: A Phase III Trial of Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases
    Eligibility Criteria - NCT03550391 *This information has been extracted from " www.clinicaltrials.gov"

  • 20191167 - Mellon Eric

  • Investigator:
    Eric Mellon
    RCname Email

    		Coordinator:

    IRB: 20191167

    		SDG: Neurological Cancer
    Disease Site(s):

    Brain and Nervous System
    Sponsor: Alliance for Clinical Trials in Oncology

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester
    UMH
    Title:

    Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared With Fractionated SRS for Resected Metastatic Brain Disease
    Eligibility Criteria - NCT04114981 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210335 - Mellon Eric

  • Investigator:
    Eric Mellon
    RCname Email

    		Coordinator:

    IRB: 20210335

    		SDG: Neurological Cancer
    Disease Site(s):

    Brain and Nervous System
    Sponsor: SCCC

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester
    Title:

    Pilot trial of spectroscopic MRI-guided, dose-escalated proton radiation therapy and bevacizumab for recurrent glioblastoma
    Eligibility Criteria - NCT05284643 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210376 - Mellon Eric

  • Investigator:
    Eric Mellon
    RCname Email

    		Coordinator:

    IRB: 20210376

    		SDG: Neurological Cancer
    Disease Site(s):

    Brain and Nervous System
    Sponsor: NRG

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester
    Title:

    Phase III Trial of Salvage Stereotactic Radiosurgery (SRS) or SRS + Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for First or Second Distant Brain Relapse After Upfront SRS with Brain Metastasis Velocity >/= 4 Brain Metastases/Year
    Eligibility Criteria - NCT04588246 *This information has been extracted from " www.clinicaltrials.gov"